Roxana Mehran, MD, on Optimal DAPT Therapies
02/21/2020
In this podcast, Roxana Mehran, MD, talks about new dual-antiplatelet therapy (DAPT) regimens and lessons learned about new DAPT from recent research.
Roxana Mehran, MD, FACC, is a professor of medicine and the director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Wiener Cardiovascular Institute at the Mount Sinai School of Medicine in New York, New York.
Additional Resources:
- Baber U, Dangas G, Cohen DJ, et al. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: rationale and design of the TWILIGHT study. Am Heart J. 2016;182:125-134. https://doi.org/10.1016/j.ahj.2016.09.006.
- Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423-2434. https://doi.org/10.1056/nejmoa1611594.
- Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Eng J Med. 2019;381(21):2032-2042. https://doi.org/10.1056/nejmoa1908419.
- Potpara TD, Mujovic N, Proietti M, et al. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials [published online October 11, 2019]. Europace. https://doi.org/10.1093/europace/euz259.
